Search





Search





Markets
/
Stocks
/
nasdaq-rcus
/

Arcus Biosciences Inc

RCUS

Add to Watchlist

25.000USD

+0.100+0.40%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

3.14BMarket Cap

LossP/E TTM



Arcus Biosciences Inc

25.000

+0.100+0.40%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arcus Biosciences Inc

Currency: USD Updated: 2026-05-13

Key Insights

Arcus Biosciences Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 79 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.45.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arcus Biosciences Inc's Score

Industry at a Glance

Industry Ranking

79 / 383

Overall Ranking

189 / 4487

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Arcus Biosciences Inc Highlights

StrengthsRisks

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 111.11% year-on-year.

Undervalued

The company’s latest PE is -7.89, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 103.26M shares, increasing 16.93% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 22.54K shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

34.455

Target Price

+38.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-13

The current financial score of Arcus Biosciences Inc is 5.65, ranking 334 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 17.00M, representing a year-over-year decrease of 39.29%, while its net profit experienced a year-over-year decrease of 14.29%.

Score

Industry at a Glance

Previous score

5.65

Change



Financials

5.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Arcus Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-05-13

The current valuation score of Arcus Biosciences Inc is 6.23, ranking 300 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.89, which is -79.42% below the recent high of -1.62 and -2.67% above the recent low of -8.10.

Score

Industry at a Glance

Previous score

6.23

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 79/383

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-13

The current earnings forecast score of Arcus Biosciences Inc is 8.00, ranking 161 out of 383 in the Biotechnology & Medical Research industry. The average price target is 32.00, with a high of 56.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

34.455

Target Price

+38.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Arcus Biosciences Inc

RCUS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

Beigene Ltd

ONC

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-13

The current price momentum score of Arcus Biosciences Inc is 8.87, ranking 68 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 29.06 and the support level at 20.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.87

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.309

Neutral

RSI(14)

53.530

Neutral

STOCH(KDJ)(9,3,3)

35.215

Neutral

ATR(14)

1.250

Low Volatility

CCI(14)

-49.283

Neutral

Williams %R

60.932

Sell

TRIX(12,20)

0.458

Sell

StochRSI(14)

26.529

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

24.980

Buy

MA10

25.419

Sell

MA20

25.021

Sell

MA50

23.383

Buy

MA100

22.508

Buy

MA200

19.203

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-13

The current institutional shareholding score of Arcus Biosciences Inc is 7.00, ranking 83 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.11%, representing a quarter-over-quarter increase of 34.03%. The largest institutional shareholder is Steven Cohen, holding a total of 3.28M shares, representing 2.61% of shares outstanding, with 3.69% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences, Inc

31.42M

BlackRock Institutional Trust Company, N.A.

12.17M

+20.95%

Suvretta Capital Management, LLC

5.19M

+40.66%

Wellington Management Company, LLP

5.18M

+309.43%

State Street Investment Management (US)

4.58M

+34.82%

Woodline Partners LP

3.77M

+0.00%

Marshall Wace LLP

3.39M

Point72 Asset Management, L.P.

Star Investors

3.28M

-24.29%

Risk Assessment

Currency: USD Updated: 2026-05-13

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Arcus Biosciences Inc is 4.64, ranking 69 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.